Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults
Study sponsor: Emergent BioSolutions
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2012-05Actual
Enrollment · participants200Actual
Source updated2024-04-09Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.